Mithu
★    

India,
2023-05-04 06:59
(145 d 10:53 ago)

Posting: # 23541
Views: 918
 

 505 b(2) application & requirement of bio­equi­va­lence [Regulatives / Guidelines]

Post reply
Hello All,


My question is, "is it mandatory to have 505b(2) application bio-equivalent to current reference listed drug?"

regards,

Mithu
 
dshah
★★  

India/United Kingdom,
2023-05-05 15:38
(144 d 02:14 ago)

@ Mithu
Posting: # 23545
Views: 719
 

 505 b(2) application & requirement of bioequivalence

Post reply
Hello Mithu!

As we rely on existing PKPD relationship, toxicity data and other pharmacology data of reference drug, the BE is required.

Regards,
Divyen
 
Mithu
★    

India,
2023-05-11 09:58
(138 d 07:54 ago)

@ dshah
Posting: # 23548
Views: 638
 

 505 b(2) application & requirement of bioequivalence

Post reply
Hi Divyen,

Thank you for your reply.

regards,

Mithu
 
Achievwin
★    

US,
2023-05-05 18:08
(143 d 23:44 ago)

@ Mithu
Posting: # 23546
Views: 744
 

 505 b(2) application & requirement of bio­equi­va­lence

Post reply
Hello Mithu:

505 (b)(2) is all about the submission and marketing strategy. Most of the 505(b)(2) applications take BE route as drug Chemistry, safety and efficacy along with biopharmaceutics is already known and BE is used as a knowledge (claim) gap bridging approach. There are other means you can get 505(b)(2. Please review different guidance (FDA, EMA etc.) or white papers on 505(b)(2).

Hope this helps
 
Mithu
★    

India,
2023-05-11 09:58
(138 d 07:53 ago)

@ Achievwin
Posting: # 23549
Views: 621
 

 505 b(2) application & requirement of bio­equi­va­lence

Post reply
Hello Achievwin,

Thank you for your reply.

regards,

Mithu
 
UA Flag
Activity
 Admin contact
22,761 posts in 4,775 threads, 1,628 registered users;
14 visitors (0 registered, 14 guests [including 5 identified bots]).
Forum time: 17:52 CEST (Europe/Vienna)

Whenever a theory appears to you as the only possible one,
take this as a sign that you have neither understood the theory
nor the problem which it was intended to solve.    Karl R. Popper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5